Galapagos NV reports results for the quarter ended in December - Earnings Summary

Lakefront Biotherapeutics NV

23/02/2024 03:02

* Galapagos NV  GLPG.AS  reported quarterly adjusted
earnings of
€2.39​​ per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of
€-3.16.  The mean expectation of four analysts for the quarter
was for a loss of €3.93 per share. Wall Street expected
results to range from €-4.53 to €-3.54 per share.
    * Revenue rose 251.8% to €334.65 million from a year ago;
analysts
expected €81.51 million. 
    * Galapagos NV's reported EPS for the quarter was €2.39​.
    * The company reported quarterly net income of €157.56
million.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Galapagos NV is
€40.00 
This summary was machine generated from LSEG data February 23 at
03:01 a.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -3.93          2.39           Beat
 Sep. 30 2023      -0.96          0.39           Beat
 Jun. 30 2023      -0.83          0.08           Beat
                                  0.35